NCT03317301

Evaluate the Efficacy and Safety of HL151 Versus Talion Tab. in Pruritus Cutaneus

a Multicenter, Randomized, Double-blinded, Active-controlled, Parallel, Phase Ⅲ Study to Evaluate the Efficacy and Safety of HL151 Versus Talion Tab. in Pruritus Cutaneus

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 189 (actual)
• Sponsor: Hanlim Pharm. Co., Ltd. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

a Multicenter, Randomized, Double-blinded, Active-controlled, Parallel, Phase Ⅲ Study to Evaluate the Efficacy and Safety of HL151 versus Talion Tab. in Pruritus cutaneus. \- Endpoint: VAS Score Change, Investigator's assessment of overall treatment

Conditions

• Pruritus

Interventions

Type	Name	Description
DRUG	HL151	2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (1Tab)+Talion Tab (Placebo)(1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (Placebo)(1Tab)
DRUG	Talion Tab	2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (Placebo)(1Tab)+Talion Tab (1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (1Tab)

Timeline

• Start date: 2017-05-17
• Primary completion: 2017-11-13
• Completion: 2018-01-30
• First posted: 2017-10-23
• Last updated: 2018-08-28

Locations

1 site across 1 country: South Korea